多发性硬化症患者与疾病修正疗法：对针对2019冠状病毒病和严重急性呼吸综合征冠状病毒2疫苗接种的免疫反应的影响
Multiple Sclerosis Patients and Disease Modifying Therapies: Impact on Immune Responses against COVID-19 and SARS-CoV-2 Vaccination.
作者信息
Golshani Maryam, Hrdý Jiří
机构信息
Institute of Immunology and Microbiology, Faculty of Medicine, Charles University, 128 00 Prague, Czech Republic.
出版信息
Vaccines (Basel). 2022 Feb 11;10(2):279. doi: 10.3390/vaccines10020279.
Abstract
This article reviews the literature on SARS-CoV-2 pandemic and multiple sclerosis (MS). The first part of the paper focuses on the current data on immunopathology of SARS-CoV-2 and leading vaccines produced against COVID-19 infection. In the second part of the article, we discuss the effect of Disease Modifying Therapies (DMTs) on COVID-19 infection severity or SARS-CoV-2 vaccination in MS patients plus safety profile of different vaccine platforms in MS patients.
摘要
本文综述了关于严重急性呼吸综合征冠状病毒2（SARS-CoV-2）大流行与多发性硬化症（MS）的文献。论文的第一部分聚焦于SARS-CoV-2免疫病理学的当前数据以及针对2019冠状病毒病（COVID-19）感染所研发的主要疫苗。在本文的第二部分，我们讨论了疾病修正治疗（DMTs）对MS患者感染COVID-19的严重程度或接种SARS-CoV-2疫苗的影响，以及不同疫苗平台在MS患者中的安全性。
相似文献
1
Multiple Sclerosis Patients and Disease Modifying Therapies: Impact on Immune Responses against COVID-19 and SARS-CoV-2 Vaccination.多发性硬化症患者与疾病修正疗法：对针对2019冠状病毒病和严重急性呼吸综合征冠状病毒2疫苗接种的免疫反应的影响
Vaccines (Basel). 2022 Feb 11;10(2):279. doi: 10.3390/vaccines10020279.
2
Impact of mass vaccination on SARS-CoV-2 infections among multiple sclerosis patients taking immunomodulatory disease-modifying therapies in England.大规模疫苗接种对英国使用免疫调节疾病修正疗法的多发性硬化症患者中 SARS-CoV-2 感染的影响。
Mult Scler Relat Disord. 2022 Jan;57:103458. doi: 10.1016/j.msard.2021.103458. Epub 2021 Dec 5.
3
Multiple Sclerosis Disease-Modifying Therapy and the COVID-19 Pandemic: Implications on the Risk of Infection and Future Vaccination.多发性硬化症的疾病修正治疗与 COVID-19 大流行：感染风险和未来疫苗接种的影响。
CNS Drugs. 2020 Sep;34(9):879-896. doi: 10.1007/s40263-020-00756-y.
4
Discordant humoral and T cell immune responses to SARS-CoV-2 vaccination in people with multiple sclerosis on anti-CD20 therapy.抗 CD20 治疗的多发性硬化症患者对 SARS-CoV-2 疫苗接种的体液和 T 细胞免疫应答不一致。
EBioMedicine. 2021 Nov;73:103636. doi: 10.1016/j.ebiom.2021.103636. Epub 2021 Oct 16.
5
Summary of Safety and Efficacy of COVID Vaccination in Patients with Multiple Sclerosis.多发性硬化症患者 COVID 疫苗接种的安全性和有效性总结。
Eur Neurol. 2023;86(4):263-276. doi: 10.1159/000529982. Epub 2023 Mar 4.
6
Clinical course and outcome of SARS-CoV-2 infection in multiple sclerosis patients treated with disease-modifying therapies - the Polish experience.在接受疾病修正治疗的多发性硬化症患者中，SARS-CoV-2 感染的临床病程和结局-波兰经验。
Neurol Neurochir Pol. 2021;55(2):212-222. doi: 10.5603/PJNNS.a2021.0031. Epub 2021 Apr 15.
7
Safety of Vaccines against SARS-CoV-2 among Polish Patients with Multiple Sclerosis Treated with Disease-Modifying Therapies.接受疾病修正治疗的波兰多发性硬化症患者接种新型冠状病毒疫苗的安全性
Vaccines (Basel). 2022 May 12;10(5):763. doi: 10.3390/vaccines10050763.
8
B- and T-Cell Responses After SARS-CoV-2 Vaccination in Patients With Multiple Sclerosis Receiving Disease Modifying Therapies: Immunological Patterns and Clinical Implications.多发性硬化症患者在接受疾病修正治疗的情况下接种 SARS-CoV-2 疫苗后的 B 细胞和 T 细胞反应：免疫模式和临床意义。
Front Immunol. 2022 Jan 17;12:796482. doi: 10.3389/fimmu.2021.796482. eCollection 2021.
9
Vaccine Response in Patients With Multiple Sclerosis Receiving Teriflunomide.接受特立氟胺治疗的多发性硬化症患者的疫苗反应
Front Neurol. 2022 Feb 28;13:828616. doi: 10.3389/fneur.2022.828616. eCollection 2022.
10
Vaccine hesitancy among people with multiple sclerosis.多发性硬化症患者中的疫苗犹豫。
Mult Scler Relat Disord. 2021 Nov;56:103236. doi: 10.1016/j.msard.2021.103236. Epub 2021 Sep 2.
引用本文的文献
1
COVID-19 vaccines are not associated with axonal injury in patients with multiple sclerosis.COVID-19 疫苗与多发性硬化症患者的轴突损伤无关。
Front Immunol. 2024 Aug 22;15:1439393. doi: 10.3389/fimmu.2024.1439393. eCollection 2024.
2
Immunogenicity, clinical efficacy, and safety of the sinopharm (BBIBP-CorV) SARS-CoV-2 vaccine among people with multiple sclerosis receiving disease-modifying therapies: a prospective cohort study.在接受疾病修正治疗的多发性硬化症患者中，国药（BBIBP-CorV）SARS-CoV-2 疫苗的免疫原性、临床疗效和安全性：一项前瞻性队列研究。
BMC Neurol. 2024 Aug 20;24(1):291. doi: 10.1186/s12883-024-03793-y.
3
SARS-CoV-2-Specific Immune Cytokine Profiles to mRNA, Viral Vector and Protein-Based Vaccines in Patients with Multiple Sclerosis: Beyond Interferon Gamma.多发性硬化症患者针对基于mRNA、病毒载体和蛋白质的疫苗的SARS-CoV-2特异性免疫细胞因子谱：超越γ干扰素
Vaccines (Basel). 2024 Jun 19;12(6):684. doi: 10.3390/vaccines12060684.
4
Potential beneficial effect of IFN-β1a and ocrelizumab in people with MS during the COVID-19 pandemic.COVID-19 大流行期间 IFN-β1a 和奥瑞珠单抗对 MS 患者的潜在有益作用。
Acta Neurol Belg. 2024 Apr;124(2):447-455. doi: 10.1007/s13760-023-02421-9. Epub 2023 Nov 14.
5
Current Updates on the Diagnosis and Management of Multiple Sclerosis for the General Neurologist.普通神经科医生对多发性硬化症诊断与治疗的最新进展
J Clin Neurol. 2023 May;19(3):217-229. doi: 10.3988/jcn.2022.0208.
6
Short- and Long-Term Humoral and Cellular Immune Responses to SARS-CoV-2 Vaccination in Patients with Multiple Sclerosis Treated with Disease-Modifying Therapies.接受疾病修正治疗的多发性硬化症患者对SARS-CoV-2疫苗接种的短期和长期体液免疫及细胞免疫反应
Vaccines (Basel). 2023 Apr 3;11(4):786. doi: 10.3390/vaccines11040786.
7
Summary of Safety and Efficacy of COVID Vaccination in Patients with Multiple Sclerosis.多发性硬化症患者 COVID 疫苗接种的安全性和有效性总结。
Eur Neurol. 2023;86(4):263-276. doi: 10.1159/000529982. Epub 2023 Mar 4.
8
SARS-CoV-2 infection in multiple sclerosis patients: interaction with treatments, adjuvant therapies, and vaccines against COVID-19.SARS-CoV-2 感染多发性硬化症患者：与 COVID-19 治疗、辅助疗法和疫苗的相互作用。
J Neurol. 2022 Sep;269(9):4581-4603. doi: 10.1007/s00415-022-11237-1. Epub 2022 Jul 5.
9
Watch out for neuromyelitis optica spectrum disorder onset or clinical relapse after COVID-19 vaccination: What neurologists need to know?警惕 COVID-19 疫苗接种后出现视神经脊髓炎谱系障碍或临床复发：神经科医生需要了解什么？
Mult Scler Relat Disord. 2022 Sep;65:103960. doi: 10.1016/j.msard.2022.103960. Epub 2022 Jun 10.
本文引用的文献
1
Humoral and T-cell responses to SARS-CoV-2 vaccination in multiple sclerosis patients treated with ocrelizumab.奥瑞珠单抗治疗多发性硬化症患者对 SARS-CoV-2 疫苗的体液和 T 细胞反应。
Mult Scler Relat Disord. 2022 Jan;57:103382. doi: 10.1016/j.msard.2021.103382. Epub 2021 Nov 9.
2
Immunogenicity and Safety of a Third SARS-CoV-2 Vaccine Dose in Patients With Multiple Sclerosis and Weak Immune Response After COVID-19 Vaccination.COVID-19 疫苗接种后多发性硬化症患者对第三剂 SARS-CoV-2 疫苗的免疫原性和安全性：免疫应答较弱。
JAMA Neurol. 2022 Mar 1;79(3):307-309. doi: 10.1001/jamaneurol.2021.5109.
3
Immunological and clinical efficacy of COVID-19 vaccines in immunocompromised populations: a systematic review.新冠病毒疫苗在免疫功能低下人群中的免疫和临床疗效：一项系统评价
Clin Microbiol Infect. 2022 Feb;28(2):163-177. doi: 10.1016/j.cmi.2021.09.036. Epub 2021 Nov 17.
4
Short-term effectiveness of COVID-19 vaccines in immunocompromised patients: A systematic literature review and meta-analysis.COVID-19 疫苗在免疫功能低下患者中的短期疗效：系统文献回顾和荟萃分析。
J Infect. 2022 Mar;84(3):297-310. doi: 10.1016/j.jinf.2021.12.035. Epub 2022 Jan 1.
5
Efficacy of a third BNT162b2 mRNA COVID-19 vaccine dose in patients with CLL who failed standard 2-dose vaccination.三剂 BNT162b2 mRNA COVID-19 疫苗在标准两剂接种失败的 CLL 患者中的疗效。
Blood. 2022 Feb 3;139(5):678-685. doi: 10.1182/blood.2021014085.
6
Efficacy of booster doses in augmenting waning immune responses to COVID-19 vaccine in patients with cancer.在癌症患者中，加强针在增强对 COVID-19 疫苗的免疫应答方面的效果。
Cancer Cell. 2022 Jan 10;40(1):3-5. doi: 10.1016/j.ccell.2021.11.006. Epub 2021 Nov 16.
7
COVID-19 in B Cell-Depleted Patients After Rituximab: A Diagnostic and Therapeutic Challenge.利妥昔单抗治疗后 B 细胞耗竭患者的 COVID-19：诊断和治疗挑战。
Front Immunol. 2021 Nov 3;12:763412. doi: 10.3389/fimmu.2021.763412. eCollection 2021.
8
COVID-19 Severity in Multiple Sclerosis: Putting Data Into Context.COVID-19 严重程度在多发性硬化症中的表现：将数据置于具体情境中。
Neurol Neuroimmunol Neuroinflamm. 2021 Nov 9;9(1). doi: 10.1212/NXI.0000000000001105. Print 2022 Jan.
9
Humoral Response Induced by Prime-Boost Vaccination with the ChAdOx1 nCoV-19 and mRNA BNT162b2 Vaccines in a Teriflunomide-Treated Multiple Sclerosis Patient.在一名接受特立氟胺治疗的多发性硬化症患者中，使用ChAdOx1 nCoV-19和mRNA BNT162b2疫苗进行初免-加强免疫接种诱导的体液反应。
Vaccines (Basel). 2021 Oct 6;9(10):1140. doi: 10.3390/vaccines9101140.
10
Antibody Responses after a Third Dose of COVID-19 Vaccine in Kidney Transplant Recipients and Patients Treated for Chronic Lymphocytic Leukemia.肾移植受者和慢性淋巴细胞白血病治疗患者接种第三剂新冠疫苗后的抗体反应
Vaccines (Basel). 2021 Sep 23;9(10):1055. doi: 10.3390/vaccines9101055.
Zotero 插件